ArticleThe European respiratory journal2021
Instability of sputum molecular phenotypes in U-BIOPRED severe asthma.
Article in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The Evolving Role of Artificial Intelligence in Pediatric Asthma Management: Opportunities and Challenges for Modern Healthcare.Journal of personalized medicine · 2026Review
- Integrated Single-Cell Profiling Reveals TL1A as a Biomarker and Driver of Type 2 Inflammation via Macrophage-Dependent Immunoregulation in Asthma.Research (Washington, D.C.) · 2026Article
- Next Decade Research in Asthma: Broad Omics-Based Exploration Versus Targeted Airway Epithelium Studies.Journal of clinical medicine · 2025Review
- Type 2 gene expression signature in severe asthma associates with more advanced airway remodeling.Clinical and translational allergy · 2025Article
- Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.Pulmonary therapy · 2025Review
- Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts.The Lancet. Respiratory medicine · 2025Article
- Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies.The European respiratory journal · 2024Review
- Asthma Pathogenesis: Phenotypes, Therapies, and Gaps: Summary of the Aspen Lung Conference 2023.American journal of respiratory cell and molecular biology · 2024Review
- Endotypes of severe neutrophilic and eosinophilic asthma from multi-omics integration of U-BIOPRED sputum samples.Clinical and translational medicine · 2024Article
- Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics.ERJ open research · 2023Article
- Non-eosinophilic asthma in nonsteroidal anti-inflammatory drug exacerbated respiratory disease.Clinical and translational allergy · 2023Article
- Clinical Trial Design Innovations for Precision Medicine in Asthma.Advances in experimental medicine and biology · 2023Article
- Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.Journal of personalized medicine · 2022Review
- Mechanisms of Mast Cell Activation in Severe Asthma: Beyond IgE.American journal of respiratory and critical care medicine · 2022Article
- Challenges in severe asthma: Do we need new drugs or new biomarkers?Frontiers in medicine · 2022Review
- Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease.Breathe (Sheffield, England) · 2021Review
- [How to Approach Non Eosinophilic Asthma? Results of a Survey Conducted by the SEPAR Emerging Asthma Group].Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.